Cell Therapeutics, Inc. Annual Shareholders Meeting Scheduled for September 25

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- On Tuesday, September 25, 2007, at 2:00 PM Central European Time/8:00 AM Eastern Time/5:00 AM Pacific Time members of Cell Therapeutics, Inc.'s (CTI) (MTAX: CTIC) management team will host the Company’s Annual Shareholders Meeting at the Borsa Italiana in Milan, Italy. The meeting will be webcast live on CTI’s website at http://www.cticseattle.com and archived for replay.

Questions for management or the Board of Directors may be submitted through Monday, September 24 at 5:00 PM Central European Time/11:00 AM Eastern Time/8:00 AM Pacific Time to invest@ctiseattle.com or investors.italia@ctimilano.com. For more information about the meeting, please visit the CTI website.

Annual Shareholders Meeting Tuesday, September 25 Conference Call 5:00 AM Pacific/ 8:00 AM Eastern / 2:00 PM CET 1-866-551-6755 (US Participants) 800-986980 (Italy) 44-08452450356 (International) Call-back numbers for post listening: 1-866-247-4222 (US Participants) 44-01452-550000 (International) Entry code: 17761691# (English) Entry code: 17759359# (Italian) Live webcast with slides at http://www.cticseattle.com Archived for post viewing approximately 2 hours after the meeting ends Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: media@ctiseattle.comhttp://www.cticseattle.com/media.htm Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: invest@ctiseattle.comhttp://www.cticseattle.com/investors.htm In Europe Cell Therapeutics Europe S.r.l. Mauro Premi T: +39 02 61035700 F: +39 02 61035601 E: mauro.premi@ctimilano.com

Cell Therapeutics, Inc.

CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, fax, +1-206-272-4434,media@ctiseattle.com, or investors, Leah Grant, +1-206-282-7100, fax,+1-206-272-4434, invest@ctiseattle.com, or Europe, Mauro Premi, +39 0261035700, mauro.premi@ctimilano.com, all of Cell Therapeutics, Inc.

MORE ON THIS TOPIC